Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis

被引：54
作者：
Pinto, Lana C. [1 ]
Falcetta, Mariana R. [1 ]
Rados, Dimitris, V [1 ]
Leitao, Cristiane B. [1 ]
Gross, Jorge L. [1 ]
机构：
[1] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Div Endocrinol, Ramiro Barcelos St 2350,Predio 12,4th Floor, BR-90035903 Porto Alegre, RS, Brazil
来源：
SCIENTIFIC REPORTS | 2019年 / 9卷 / 1期
关键词：
EXOCRINE PANCREAS; NO EVIDENCE; ENDOCRINE; RISK; LIRAGLUTIDE; EXENATIDE; THERAPY; RATS;
D O I：
10.1038/s41598-019-38956-2
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
We aimed to assess if GLP-1 agonists are associated with pancreatic cancer. Systematic review and meta-analysis of randomized trials with GLP-1 agonists as an intervention was performed. Trial sequential analysis (TSA) was performed to assess if the available information is sufficient to reject this association. Twelve trials met the study criteria, with a total of 36, 397 patients. GLP-1 analogues did not increase the risk for pancreatic cancer when compared to other treatments (OR 1.06; 95% CI 0.67 to 1.67; I-2 14%). TSA confirmed that enough patients were randomized and again no association of the medications and pancreatic cancer was observed considering a NNH of 1000 and the short mean follow-up of the included trials (1.7 years). Larger studies with longer duration would be required to exclude a greater NNH and to aside concerns regarding possible influence of study duration and the outcome.
引用
收藏
页数：6
相关论文
共 25 条
[1]  
[Anonymous], FDA DRUG SAF COMM FD
[2]  
[Anonymous], 2016, DIABETES
[3]  
[Anonymous], 2011, BMJ, V343, pd5928, DOI [DOI 10.1136/BMJ.D5928, 10.1136/bmj.d5928]
[4]   Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study [J].
Azoulay, Laurent ;
Filion, Kristian B. ;
Platt, Robert W. ;
Dahl, Matthew ;
Dormuth, Colin R. ;
Clemens, Kristin K. ;
Durand, Madeleine ;
Juurlink, David N. ;
Targownik, Laura E. ;
Turin, Tanvir C. ;
Paterson, J. Michael ;
Ernst, Pierre .
BMJ-BRITISH MEDICAL JOURNAL, 2016, 352
[5]   Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors [J].
Butler, Alexandra E. ;
Campbell-Thompson, Martha ;
Gurlo, Tatyana ;
Dawson, David W. ;
Atkinson, Mark ;
Butler, Peter C. .
DIABETES, 2013, 62 (07) :2595-2604
[6]   The biology of incretin hormones [J].
Drucker, DJ .
CELL METABOLISM, 2006, 3 (03) :153-165
[7]   Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies [J].
Elashoff, Michael ;
Matveyenko, Aleksey V. ;
Gier, Belinda ;
Elashoff, Robert ;
Butler, Peter C. .
GASTROENTEROLOGY, 2011, 141 (01) :150-156
[8]   Pancreatitis: A Potential Complication of Liraglutide? [J].
Franks, Andrea S. ;
Lee, Phillip H. ;
George, Christa M. .
ANNALS OF PHARMACOTHERAPY, 2012, 46 (11) :1547-1553
[9]   A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs [J].
Funch, D. ;
Gydesen, H. ;
Tornoe, K. ;
Major-Pedersen, A. ;
Chan, K. A. .
DIABETES OBESITY & METABOLISM, 2014, 16 (03) :273-275
[10]   GRADE:: Incorporating considerations of resources use into grading recommendations [J].
Guyatt, Gordon H. ;
Oxman, Andrew D. ;
Kunz, Regina ;
Jaeschke, Roman ;
Helfand, Mark ;
Liberati, Alessandro ;
Vist, Gunn E. ;
Schunemann, Holger J. .
BRITISH MEDICAL JOURNAL, 2008, 336 (7654) :1170-1173
123